41239-39-8

Usage

Uses

Used in Pharmaceutical Manufacturing:
METHYL-(2-PIPERIDIN-1-YL-ETHYL)-AMINE is used as a precursor in the synthesis of pharmaceuticals for its ability to contribute to the development of medications such as antihistamines and antidepressants, playing a crucial role in the treatment of various medical conditions.
Used in Organic Synthesis:
In the field of organic synthesis, METHYL-(2-PIPERIDIN-1-YL-ETHYL)-AMINE is utilized as a reagent, facilitating the creation of other organic compounds, thereby expanding its applications in research and industrial processes.
Used in Research and Industrial Applications:
METHYL-(2-PIPERIDIN-1-YL-ETHYL)-AMINE is also found in research and industrial applications, where its unique structural features and reactivity make it a valuable component for the development of new chemical entities and processes.
Its diverse applications make METHYL-(2-PIPERIDIN-1-YL-ETHYL)-AMINE a compound of significant interest to medicinal chemists and professionals in the pharmaceutical and fine chemical industries, who rely on its properties to innovate and advance in their respective fields.

InChI:InChI=1/C8H18N2/c1-9-5-8-10-6-3-2-4-7-10/h9H,2-8H2,1H3

Upstream product

• 2008-75-5 N-chloroethylpiperidine hydrochloride 
• 74-89-5 methylamine 
• 27578-60-5 1-(2-aminoethyl)piperidine 
• 541-41-3 chloroformic acid ethyl ester 
• 1932-03-2 2-(piperidin-4-yl)ethyl chloride 
• 593-51-1 methylamine hydrochloride 
• 1192123-85-5 benzyl methyl(2-piperidin-1-ylethyl)carbamate 

Downstream Products

• 102896-66-2 4-[methyl-(2-piperidino-ethyl)-amino]-2,2-diphenyl-butyronitrile 
• 102947-07-9 6-[methyl-(2-piperidino-ethyl)-amino]-2,2-diphenyl-hexanenitrile 
• 103101-03-7 7-[methyl-(2-piperidino-ethyl)-amino]-2,2-diphenyl-heptanenitrile 
• 111978-15-5 4-{2-[methyl-(2-piperidino-ethyl)-amino]-ethoxy}-2,2-diphenyl-butyronitrile 
• 100104-99-2 N-methyl-N-(2-piperidino-ethyl)-benzilamide 
• 138357-12-7 2-(3,4-Dichloro-phenyl)-N-methyl-N-(2-piperidin-1-yl-ethyl)-acetamide 
• 147238-84-4 Carbonic acid benzyl ester 2,6-dimethoxy-4-((5R,5aR,8aR,9S)-9-{2-[methyl-(2-piperidin-1-yl-ethyl)-amino]-ethyl}-6-oxo-5,5a,6,8,8a,9-hexahydro-furo[3',4':6,7]naphtho[2,3-d][1,3]dioxol-5-yl)-phenyl ester 
• 104176-47-8 (4-benzhydryloxy-butyl)-methyl-(2-piperidino-ethyl)-amine 
• 104217-55-2 2-cyclohexyl-6-[methyl-(2-piperidino-ethyl)-amino]-2-phenyl-hexanenitrile 
• 103756-42-9 [4-(4,4'-dichloro-benzhydryloxy)-butyl]-methyl-(2-piperidino-ethyl)-amine 
• 119112-21-9 4,4'-dimethoxy-α-[methyl-(2-piperidino-ethyl)-amino]-deoxybenzoin 
• 114281-37-7 1-[2-(benziloyl-methyl-amino)-ethyl]-1-methyl-piperidinium; bromide 
• 117204-37-2 (3-cyano-3,3-diphenyl-propyl)-dimethyl-[2-(1-methyl-piperidinium-1-yl)-ethyl]-ammonium; diiodide 

Relevant academic research and scientific papers

Asymmetric synthesis catalyzed by chiral ferrocenylphosphine-transition metal complexes IX. Preparation of chiral ferrocenylbisphosphines containing an aminoalkyl side chain

New optically active ferrocenylbisphosphines containing an aminoalkyl pendant side chain were prepared.They are (R)-N-methyl-N-(2-piperidino)ethyl-1-ethylamines, where aryl groups on the phosphorus atoms are 4-CF3C

Degradation of Organic Cations under Alkaline Conditions

Understanding the degradation mechanisms of organic cations under basic conditions is extremely important for the development of durable alkaline energy conversion devices. Cations are key functional groups in alkaline anion exchange membranes (AAEMs), and AAEMs are critical components to conduct hydroxide anions in alkaline fuel cells. Previously, we have established a standard protocol to evaluate cation alkaline stability within KOH/CD3OH solution at 80 °C. Herein, we are using the protocol to compare 26 model compounds, including benzylammonium, tetraalkylammonium, spirocyclicammonium, imidazolium, benzimidazolium, triazolium, pyridinium, guanidinium, and phosphonium cations. The goal is not only to evaluate their degradation rate, but also to identify their degradation pathways and lead to the advancement of cations with improved alkaline stabilities.

ERBB/BTK INHIBITORS

Disclosed are compounds inhibiting ErbBs (e. g., EGFR or Her 2), especially mutant forms of ErbBs, and BTK, pharmaceutically acceptable salts, hydrates, solvates or stereoisomers thereof and pharmaceutical compositions comprising the compounds. The compou

C-4" POSITION SUBSTITUTED MACROLIDE DERIVATIVE

A macrolide compound represented by the formula (I) effective against erythromycin resistant bacteria (for example, resistant pneumococci, streptococci and mycoplasmas).

SORDARIN DERIVATIVES FOR PREVENTING OR TREATING INFECTIOUS DISEASES CAUSED BY PATHOGENIC MICROORGANISMS

This invention relates to a new sordarin derivative or a pharmaceutically acceptable salt thereof, which has antimicrobial activities (especially, antifungal activities), to process for preparation thereof, to a pharmaceutical composition comprising the same, and to a method for prophylactic and/or therapeutic treatment of infectious diseases in a human being or an animal.

Compounds derived from aryl carbamates, preparation thereof and uses of same

The invention concerns novel compounds, preparation and uses of same, particularly therapeutic. More particularly, the invention concerns compounds derived from arylcarbamates, preparation and uses of same, particularly in the field of human or animal health. The inventive compounds are preferably ligands of serotoninergic 5-HT4 receptors, and can therefore be used in the therapeutic or prophylactic treatment of any disorder involving a 5-HT4 receptor. The invention also relates to pharmaceutical compositions comprising such compounds, preparation and uses thereof, and treatment methods using said compounds.

Novel analogs of the σ receptor ligand BD1008 attenuate cocaine-induced toxicity in mice

Previous studies have shown that BD1008 (N-[2-(3,4-dichlorophenyl)ethyl]-N- methyl-2-(1-pyrrolidinyl)ethylamine) and related analogs attenuate the toxicity and stimulant effects of cocaine through antagonism of σ receptors. In the present study, six analogs of BD1008 (UMB 98-103) were synthesized and evaluated in receptor binding and behavioral studies. Competition binding studies confirmed that all six compounds have high affinity for σ1 receptors, moderate affinity for σ2 receptors, and low to negligible affinity for monoamine transporters, opioid, N-methyl-D-aspartate, dopamine, and 5-HT receptors. In behavioral pharmacological studies, pretreatment of mice with UMB 100, UMB 101, or UMB 103 significantly attenuated cocaine-induced convulsions and lethality. Together with earlier studies, the data suggest that analogs of BD1008 are promising medication development leads for reducing the toxicity of cocaine.

Search for histamine H3 receptor ligands with combined inhibitory potency at histamine N-methyltransferase: ω- piperidinoalkanamine derivatives

In an effort to design new hybrid compounds with dual properties, i.e. binding affinity at histamine H3 receptors and inhibitory potency at the catabolic enzyme histamine Nτ-methyltransferase (HMT), a novel series of 1-substituted piperidine derivatives was synthesized. This alicyclic heterocycle is structurally linked via aminoalkyl spacers of variable lengths to additional aromatic carbo- or heterocycles. These new hybrid drugs were pharmacologically evaluated regarding their binding affinities at recombinant human H3 receptors, stably expressed in CHO cells, and in a functional assay for their inhibitory potencies at rat kidney HMT. All compounds investigated proved to be H3 receptor ligands with binding affinities in the micro- to nanomolar concentration range despite significant differences in the type of the aromatic moiety introduced. The most potent compound in this series was the quinoline derivative 20 (Ki = 5.6 nM). Likewise, all new ligands studied showed impressive HMT inhibitory activities. Here, compounds 5, 10, 14, and 18-20 exhibited submicromolar potencies (IC50 = 0.061 -0.56 μM). The aminomethylated quinoline 19 showed almost the same, well balanced nanomolar activities on both targets. In this study, new hybrid compounds with a dual mode biological action were developed. These pharmacological agents are valuable leads for further development and candidates for treatment of histamine-dependent disorders.

Development of a new class of nonimidazole histamine H3 receptor ligands with combined inhibitory histamine N-methyltransferase activity

In search of novel ways to enhance histaminergic neurotransmission in the central nervous system, a new class of nonimidazole histamine H3 receptor ligands were developed that simultaneously possess strong inhibitory activity on the main histamine metabolizing enzyme, histamine N-methyltransferase (HMT). The novel compounds contain an aminoquinoline moiety, which is an important structural feature for HMT inhibitory activity, connected by different spacers to a piperidino group (for H3 receptor antagonism). Variation of the spacer structure provides two different series of compounds. One series, having only an alkylene spacer between the basic centers, led to highly potent HMT inhibitors with moderate to high affinity at human histamine H3 receptors. The second series possesses a p-phenoxypropyl spacer, which may be extended by another alkylene chain. This latter series also showed strong inhibitory activity on HMT, and in most cases, the H3 receptor affinity even surpassed that of the first series. One of the most potent compounds with this dual mode of action is 4-(4-(3-piperidinopropoxy)phenylamino)quinoline (34) (hH3, Ki = 0.09 nM; HMT, IC50 = 51 nM). This class of compounds showed high antagonist potency and good H3 receptor selectivity in functional assays in guinea pig on H1, H2, and H3 receptors. Because of low or missing in vivo activity of two selected compounds, the proof of concept of these valuable pharmacological tools for the supposed superior overall enhancing effect on histaminergic neurotransmission failed to appear hitherto.

Substituted 1-phenyl-2-cyclopropylmethylamines with high affinity and selectivity for sigma sites

A series of 1-phenyl-2-cyclopropylmethylamines structurally related to (+)- and (-)-MPCB were synthesized and their binding affinities for σ1, σ2, opioid and dopamine (D2) receptors were evaluated. Substitution of the cis-N-normetazocine with different aminic moieties provided compounds with high affinity and selectivity for σ binding sites with respect to opioid and dopamine (D2) receptors. The observed increase in σ2 affinity as compared to the parent (+)-MPCB, supports the idea that the particular stereochemistry of (+)-cis-N-normetazocine affects σ1 selectivity but does not affect σ1 affinity. The (±)-cis isomers of methyl 2-[(1-adamantylamino)methyl]-1-phenylcyclopropane-1-carboxylate (18) displayed a higher affinity and selectivity for the σ1 and σ2 receptor subtypes compared to the (±)-trans 19. Interestingly, the enantiomer (-)-cis 18 displayed a preference for σ1 receptor subtype whereas the (+)-cis 18 did for σ2. These results prompt us to synthesize compounds with modification of nitrogen and carboxyl groups. The compounds obtained showed high affinities and selectivity for σ sites. Moreover, modifications of carboxyl groups provided compounds with the highest affinities in the series. In particular, compound 25 with reverse-type ester showed a K(i) of 0.6 and 4.05nM for σ1 and σ2 binding sites, respectively. Copyright (C) 2000 Elsevier Science Ltd.